ClinicalTrials.gg
CompletedNCT03053024Updated Nov 6, 2020

Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants

An observational study in Lymphoma, Mantle-Cell, sponsored by Xian-Janssen Pharmaceutical Ltd.. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.

Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
54
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Mantle-Cell · Johnson & Johnson.

Started
2017
the only one that year
Observational
3 of 16
none open now
Registered
12th of 16
by date

Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, this one is the only one that started in 2017, is one of 3 observational ones, and was the 12th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

None of the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson is open now. The open studies under Lymphoma, Mantle-Cell, anywhere →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson as a file.
02

Study summary

The purpose of the study (retrospective and prospective) is to describe participant and disease characteristics and treatment pattern of Bortezomib treated mantle cell lymphoma (MCL) participants in China.

03

Conditions studied

  • Lymphoma, Mantle-Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study include mantle cell lymphoma (MCL) participants who were or will be treated by Bortezomib (BTZ) per routine clinical care in multiple tertiary care hospitals after January 1st 2009. Both newly diagnosed MCL participants and relapsed/refractory MCL participants will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants that have been hospitalized for MCL after January 1st 2009.
  • proven MCL as evidenced by histology with either immunohistochemistry (IHC) or t(11,14) translocation
  • Retrospective group: Participants who have finished BTZ treatment before the study initiation as judged by participating site physician
  • If participant isn't accessible for oral or written , ICF can be waived after approved by the IRB
  • Prospective group: Participants who are on BTZ at the time of study initiation or start BTZ after study initiation

Exclusion criteria

Exclusion Criteria:

  • Participants with documented diagnosis of other cancers prior to or at the presence of the diagnosis of MCL
  • Participants enrolled in interventional clinical trials of BTZ or any other drug for MCL
  • Prospective group: Participants with listed in the prescribing information of BTZ
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
54 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1: Relapse/refractory MCL (rrMCL ) Participants

    Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma \[rrMCL\]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.

  • Cohort 2: Newly Diagnosed MCL Participants

    Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.

06

What researchers measure

Primary outcomes

  1. Demographic Characteristic of Participants in Prospective Group: Age

    Continuous variable (age) will be summarized using descriptive statistics.

    Time frame: Baseline

  2. Participants Disease Status (newly diagnosed MCL or relapsed/refractory mantel cell lymphoma [rrMCL]) Treated With BTZ

    Categorical variable (disease status) will be summarized using a frequency distribution with the number and percentage of participants in each category. Treatment response will be analyzed by this variable if newly diagnosed MCL patients account for more than 20 percent (%) of total.

    Time frame: Baseline

  3. Eastern Cooperative Oncology Group (ECOG) Performance Status

    A worsening in Eastern Cooperative Oncology Group (ECOG) performance status score was defined as greater than or equal to 1-point increase from Baseline. ECOG is a 5-point scale 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.

    Time frame: Baseline

  4. Ann Arbor Stage

    Ann Arbor stage can be obtained from imaging results or directly from admission records. Ann Arbor stage describes areas of involvement; Stage I(IE) - One lymph node region or extralymphatic site (IE); Stage II(IIE)- Two or more lymph node regions or at least one lymph node region plus a single localized extralymphatic site (IIE) on the same side of the diaphragm; stage III (IIIE, IIIS)-Lymph node regions or lymphoid structures (example, thymus,Waldeyer's ring) on both sides of the diaphragm with optional localised extranodal site (IIIE) or spleen (IIIS); stage IV-Diffuse or disseminated extralymphatic organ involvement.

    Time frame: Up to Follow-up (approximately 22 months)

  5. Prognostic Index Score

    Prognostic index will be summarized using descriptive statistics. For each prognostic factor, 0-3 points are given to each patient and points are summed up to a maximum of 11. Participants with 0-3 points are classified as low risk (44% of participants, median overall survival \[OS\] not reached). Participants with 4-5 points are classified as intermediate risk (35%, median OS 51 months), and patients with 6-11 points as high risk (21%, median OS 29 months).

    Time frame: Baseline

  6. Demographic Characteristic of Participants in Prospective Group: Gender

    Categorical variable (gender) will be summarized using a frequency distribution with the number and percentage of participants in each category.

    Time frame: Baseline

  7. Treatment pattern of BTZ-treated MCL participants: Route of Administration

    Primary MCL therapy with Velcade (BTZ) prior MCL treatment, combined MCL treatment and subsequent MCL treatment to extract the information on route of administration (subcutaneous \[SC\] or intravenous \[IV\]) to see if there's any outstanding factor that impacts BTZ's dose/frequency and identify the most popular usage of BTZ.

    Time frame: Up to Follow-up (approximately 22 months)

  8. Treatment Pattern of Bortezomib (BTZ) Treated MCL participants: Dose

    The cumulated dose will be summarized using descriptive statistics.

    Time frame: Up to Follow-up (approximately 22 months)

  9. Treatment Pattern of Bortezomib (BTZ) Treated MCL Participants: Frequency

    The frequency of BTZ will be summarized using a frequency distribution with the number and percentage of participants in each category.

    Time frame: Up to Follow-up (approximately 22 months)

  10. Treatment Pattern of Bortezomib (BTZ) Treated MCL Participants: Reason of BTZ Initiation/Discontinuation/Dose Adjustment

    The reason of BTZ initiation/discontinuation/dose adjustment will be described with respective number of occurrence.

    Time frame: Up to Follow-up (approximately 22 months)

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the sum of complete response \[CR\] rate (CR+ unconfirmed complete remission \[CRu\]) + Partial remission \[PR\] rate as per International Working Group (IWG 2007) criteria. These response criteria are based on the reduction in the size of the enlarged lymph node as measured by computerized tomography (CT) scan and the extent of bone marrow involvement that is determined by bone marrow aspirate and biopsy. Complete response \[CR\] defined as disappearance of all evidence of disease; CRu satisfies CR criteria, however any residual lymph node mass greater than (\>)1.5 centimeter (cm) in longest transverse dimension or extranodal site of disease (irrespective of size) must have regressed by more than 75% of the product of the longest perpendicular dimensions compared to the pretreatment baseline. PR defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.

    Time frame: Approximately 22 months

  2. Complete Response [CR] Rate (CR+ Unconfirmed Complete Remission CRu)

    The percentage of participants with CR and CRu in all participants whose treatment response data are available.

    Time frame: Approximately 22 months

  3. Partial Remission (PR) Rate

    The percentage of participants with PR in all participants whose treatment response data are available.

    Time frame: Approximately 22 months

  4. Time to Response (TTR)

    Interval between start of treatment to the first day when CR/CRu or PR was observed.

    Time frame: Approximately 22 months

  5. Duration of Response (DOR)

    Interval from the date the response was documented to the first day that Progressive Disease (PD) was observed in participants with CR/CRu or PR. PD defined as any new lesions or increase by greater than or equal to (\>=) 50% of previously involved sites from nadir.

    Time frame: Approximately 22 months

  6. Progressive-Free Survival (PFS)

    Interval between start of treatment to first day when death or PD was observed. PD defined as any new lesions or increase by \>= 50% of previously involved sites from nadir.

    Time frame: Approximately 22 months

  7. Overall survival (OS)

    Interval from the day of the start of the treatment to death, or the last date when the participant was identified to be alive whichever is late.

    Time frame: Approximately 22 months

07

Study locations

9 sites
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, 100021, China
  • Peking University Cancer Hospital
    Beijing, 100142, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • Xiangya Hospital Central South University
    Changsha, 410008, China
  • Nanfang Hospital
    Guangzhou, 510515, China
  • Jiangsu Province Hospital
    NanJing, 210029, China
  • Ruijin Hospital, Shanghai Jiao Tong University
    Shanghai, 200025, China
  • Huashan Hospital Fudan University
    Shanghai, 200040, China
  • Blood Disease Hospital of Chinese Academy of Medical Sciences
    Tianjin, 300020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Sep 2019, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2017
First posted
Feb 14, 2017
StartActual
Apr 14, 2017
Primary completionActual
Sep 30, 2019
CompletionActual
Sep 30, 2019
Last update
Nov 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03053024
Responsible party
Sponsor
First posted
Feb 14, 2017
Start date
Apr 14, 2017
Primary completion
Sep 30, 2019
Completion
Sep 30, 2019
Last update
Nov 6, 2020

Study contacts

Xian-Janssen Pharmaceutical Ltd., China Clinical Trial
study director · Xian-Janssen Pharmaceutical Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion